Artemether-Lumefantrine versus Dihydroartemisinin-Piperaquine for Treatment of Malaria: A Randomized Trial
Moses R. Kamya(University of London), Grant Dorsey(University of California System), Myers Lugemwa(Ministry of Health), Bryan Greenhouse(University of California, San Francisco), Philip J. Rosenthal(University of California, San Francisco), Ambrose Talisuna(Ministry of Health), Adoke Yeka(Malaria Consortium), Fred Wabwire‐Mangen(Makerere University Walter Reed Project), Sarah G. Staedke(University of London), John Bosco Rwakimari(Ministry of Health), François Nosten(Mahidol University), Hasifa Bukirwa(Malaria Consortium)
Cited by 176
Related Papers
International estimated fetal weight standards of the <scp>INTERGROWTH</scp>‐21<sup>st</sup> Project
|Ultrasound in Obstetrics and Gynecology|2017|358
Targeting Asymptomatic Malaria Infections: Active Surveillance in Control and Elimination
|PLoS Medicine|2013|356
Markers of Immune Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection
|The Journal of Infectious Diseases|2021|332
Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms
|Cell Reports|2021|266
FLASH: a next-generation CRISPR diagnostic for multiplexed detection of antimicrobial resistance sequences
|Nucleic Acids Research|2019|262